Form 4 Filing for Allogene Therapeutics, Inc.

Humer Franz B, a director at Allogene Therapeutics, Inc., was granted 95,400 Restricted Stock Units (RSUs) on June 18, 2026. These RSUs represent a contingent right to receive one share of the Company's Common Stock per unit. The RSUs will vest in two equal installments over one year from the grant date, contingent upon continued service. The receipt of Common Stock upon vesting is deferred until the earlier of 30 days after separation from service or a change in control, as per the Non-Employee Director Compensation Policy. The reporting owner has elected to defer the receipt of shares.